Woodley Announces the Appointment of Vijay Manchha
Woodley Equipment Company, a leading specialist medical and laboratory equipment supplier to the Clinical Trials industry has welcomed a new member to their Team.
Woodley Equipment Company, a leading specialist medical and laboratory equipment supplier to the Clinical Trials industry has welcomed a new member to their Team. Vijay Manchha joins Woodley as the Business Development Manager for our Clinical Trials Division.
Vijay has comprehensive experience of the Clinical Trials Industry having previously worked for VWR and Fisher Scientific. In these roles Vijay was responsible for managing and developing varied accounts from Research and Academia to Pharmaceutical and Biotech clients.
Vijay joins Woodley at a time of expansion and growth and will be responsible for developing new business within the company’s existing global markets. Vijay will further strengthen Woodley’s ability to offer turnkey solutions to the Clinical Trials Industry.
Woodley Equipment has been a trusted supplier of equipment solutions to the Clinical Trials industry for over 20 years. Woodley is the supplier of choice to many of the largest companies in Clinical Research, as well as the partner of small and medium sized companies around the World.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
